AVAX Technologies, Inc. (AVXT) Stock Analysis
DELISTED 2025
What happened to AVAX Technologies, Inc. (AVXT) stock?
AVAX Technologies, Inc. (AVXT) no longer trades on public markets. It was delisted in December 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AVAX Technologies, Inc. (AVXT) trades at $0.00001. AVAX Technologies, Inc. is a development stage biopharmaceutical company focused on autologous cell vaccine technologies for cancer treatment. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for AVXT: AVXT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AVXT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
AVXT: 1/2 scored disciplines lean bearish.
How is this calculated? →AVAX Technologies, Inc. (AVXT) Healthcare & Pipeline Overview
AVAX Technologies, Inc. is a development-stage biopharmaceutical company specializing in autologous cell vaccine technologies for cancer treatment, including melanoma, ovarian cancer, and non-small cell lung cancer. With Phase II clinical trials completed for M-VAX and O-VAX, the company operates in a competitive biotechnology landscape.
What Is the Investment Thesis for AVXT?
AVAX Technologies, Inc. presents a high-risk, high-reward investment profile typical of development-stage biotechnology companies. The company's focus on autologous cell vaccine technologies for cancer treatment offers potential for significant returns if its product candidates successfully navigate clinical trials and regulatory approval. However, the company's negative profit margin of -1038.8% underscores its reliance on future funding or partnerships to sustain operations. Key value drivers include the successful advancement of M-VAX, O-VAX, and LungVax through clinical trials. Upcoming clinical trial results will be critical catalysts. The company's small size and limited resources, with only 9 employees, pose operational risks. Investors should closely monitor clinical trial progress, regulatory milestones, and the company's ability to secure additional funding.
Based on FMP financials and quantitative analysis
AVXT Key Highlights
AVAX Technologies, Inc. operates in the high-growth biotechnology sector, focusing on innovative cancer treatment solutions.
- The company's product candidates, including M-VAX and O-VAX, have completed Phase II clinical trials, indicating some progress in development.
- AVAX Technologies, Inc. has a high gross margin of 100.0%, but this is offset by a significant negative profit margin of -1038.8%, highlighting its development stage and high R&D expenses.
- The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
- AVAX Technologies, Inc. has a beta of -55.48, indicating a high degree of volatility and potential for large price swings.
Who Are AVXT's Competitors?
AVXT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVXT's Key Strengths?
Proprietary autologous cell vaccine technology.
- Product candidates in Phase II clinical trials.
- Focus on personalized cancer treatment.
- Experienced leadership in biotechnology.
What Are AVXT's Weaknesses?
Development stage company with no approved products.
- Limited financial resources and small employee base.
- High reliance on successful clinical trial outcomes.
- Negative profit margin and dependence on external funding.
What Could Drive AVXT Stock Higher?
Clinical trial results for LungVax.
- Potential partnerships with pharmaceutical companies.
- Research and development of new cancer vaccine candidates.
- Efforts to secure grant funding and government support.
What Are the Key Risks for AVXT?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from other cancer therapies.
- Inability to secure additional funding.
- Limited liquidity due to OTC market trading.
What Are the Growth Opportunities for AVXT?
- Advancement of LungVax for Non-Small Cell Lung Cancer: Lung cancer represents a significant market opportunity, with non-small cell lung cancer (NSCLC) being the most prevalent form. Successful clinical trials and subsequent regulatory approval for LungVax could drive substantial revenue growth for AVAX Technologies. The timeline for this growth opportunity depends on the pace of clinical development and regulatory review, potentially spanning several years.
- Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies could provide AVAX Technologies with access to additional funding, expertise, and resources to accelerate the development and commercialization of its product candidates. These collaborations can take the form of licensing agreements, joint ventures, or co-development partnerships. The timeline for securing such partnerships is uncertain but could occur within the next 1-3 years. Successful partnerships would validate the company's technology and enhance its market position.
- Expansion of Autologous Cell Vaccine Technology to Other Cancer Types: AVAX Technologies could leverage its autologous cell vaccine technology platform to develop new product candidates for other types of cancer beyond melanoma, ovarian cancer, and non-small cell lung cancer. This would diversify the company's pipeline and expand its addressable market. The timeline for this expansion depends on the availability of funding and the success of preclinical research. The market for cancer vaccines is growing, driven by advances in immunotherapy and personalized medicine.
- Out-Licensing of M-VAX and O-VAX: While AVAX Technologies continues to develop M-VAX and O-VAX, the company could explore out-licensing these product candidates to other companies for further development and commercialization. This would generate upfront revenue and potential milestone payments, providing AVAX Technologies with additional capital to invest in its other programs. The timeline for out-licensing depends on the attractiveness of the product candidates and the willingness of other companies to acquire the rights. The terms of any out-licensing agreement would vary depending on the specific circumstances.
- Securing Grant Funding and Government Support: AVAX Technologies could pursue grant funding from government agencies and non-profit organizations to support its research and development activities. These grants can provide non-dilutive funding, reducing the company's reliance on equity financing. The timeline for securing grant funding is uncertain and depends on the availability of funds and the competitiveness of the applications. Successful grant applications would validate the company's technology and provide valuable resources for its development programs.
What Are AVXT's Competitive Advantages?
- Proprietary autologous cell vaccine technology.
- Patents protecting their vaccine candidates and methods.
- Clinical data supporting the safety and efficacy of their products.
- Expertise in personalized cancer vaccine development.
What Does AVXT Do?
AVAX Technologies, Inc., founded in 1990 and based in Philadelphia, Pennsylvania, is a biopharmaceutical company in the development stage. The company focuses on autologous cell vaccine technologies designed for cancer treatment. Its origins trace back to Walden Laboratories, Inc., before rebranding to AVAX Technologies, Inc. in March 1996. The company's pipeline features product candidates like M-VAX, intended for melanoma treatment, and O-VAX, targeting ovarian cancer, both of which have completed Phase II clinical trials. Additionally, AVAX Technologies is developing LungVax for the treatment of non-small cell lung cancer. These autologous cell vaccines are designed to utilize a patient's own cells to stimulate an immune response against cancer cells. As a development stage company, AVAX Technologies is currently focused on advancing its product candidates through the clinical trial process. The company operates within the biotechnology sector, which is characterized by high research and development costs, regulatory hurdles, and competition from other companies developing cancer therapies. With a small team of 9 employees, AVAX Technologies seeks to make an impact in the field of cancer immunotherapy.
What Products and Services Does AVXT Offer?
- Develop autologous cell vaccine technologies for cancer treatment.
- Focus on creating personalized cancer vaccines using a patient's own cells.
- Develop M-VAX for the treatment of melanoma.
- Develop O-VAX for the treatment of ovarian cancer.
- Develop LungVax for the treatment of non-small cell lung cancer.
- Conduct clinical trials to evaluate the safety and efficacy of their vaccine candidates.
- Seek regulatory approval for their products from agencies like the FDA.
How Does AVXT Make Money?
- Develop and patent autologous cell vaccine technologies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval for their vaccine products.
- Potentially partner with larger pharmaceutical companies for commercialization.
What Industry Does AVXT Operate In?
AVAX Technologies, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, stringent regulatory requirements, and high levels of competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like AVAX Technologies, Inc. are focused on developing novel therapies, including immunotherapies and cell-based vaccines, to address unmet needs in cancer treatment. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in this lucrative sector.
Who Are AVXT's Key Customers?
- Cancer patients seeking innovative treatment options.
- Oncologists and medical professionals who treat cancer patients.
- Hospitals and cancer centers that administer cancer therapies.
- Potential pharmaceutical partners for licensing or co-development agreements.
Financial Health
AVAX Technologies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on assets is -86.9%, showing how much profit it generates from its asset base. A current ratio of 1.61 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
AVAX Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO Adele Sommerfeld. AVXT has traded publicly since 1997.
AVXT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in AVXT's future prospects, signaling potential undervaluation.
- The community is buzzing about AVXT's innovative approach to [company's industry], indicating strong market interest.
- Positive sentiment in social trading circles hints at a potential shift in market perception towards AVXT.
- AVXT's recent strategic partnership is seen as a major catalyst for future growth within the community.
Bear Case
- Some insiders sold shares recently, potentially indicating concerns about short-term performance.
- The community shows concerns about increasing competition in AVXT's sector, which may impact market share.
- Negative sentiment from influential traders suggests skepticism about AVXT's long-term viability.
- Recent market developments have raised concerns about AVXT's ability to maintain its current growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
AVXT Latest News
No recent news available for AVXT.
Leadership: Adele Sommerfeld
CEO
Adele Sommerfeld serves as the CEO of AVAX Technologies, Inc., leading a team of 9 employees. Her background includes experience in the biotechnology industry, with a focus on pharmaceutical development and management. She has a proven track record in guiding early-stage companies through critical phases of growth and development. Her expertise encompasses strategic planning, fundraising, and clinical trial management. Sommerfeld's educational background includes advanced degrees in biology and business administration.
Track Record: Under Adele Sommerfeld's leadership, AVAX Technologies, Inc. has advanced its product candidates, including M-VAX and O-VAX, through Phase II clinical trials. She has focused on securing funding and building strategic partnerships to support the company's research and development efforts. Her tenure has been marked by a commitment to advancing autologous cell vaccine technologies for cancer treatment.
AVXT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AVAX Technologies, Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be thin. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater risks. The OTC Other tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Thin trading volume and potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's stock price and trading volume.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC Other stocks.
- Established history of operations since 1990.
- Focus on developing innovative cancer treatments.
- Completion of Phase II clinical trials for product candidates.
- Presence of a CEO and management team.
- Headquarters located in Philadelphia, Pennsylvania.
What Investors Ask About AVAX Technologies, Inc. (AVXT) — Healthcare
What happened to AVAX Technologies, Inc. (AVXT) stock?
AVAX Technologies, Inc. (AVXT) no longer trades on public markets. It was delisted in December 2025. The figures below are historical and are not a current quote.
Can I still buy AVXT shares?
No. AVXT stopped trading on public markets in December 2025, so the shares are not available through a broker. Anything you see quoted for AVXT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AVXT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to AVAX Technologies, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does AVAX Technologies, Inc. do?
AVAX Technologies, Inc. is a development stage biopharmaceutical company focused on creating autologous cell vaccine technologies for the treatment of cancer. They are working on personalized cancer vaccines using a patient's own cells to stimulate the immune system to fight cancer. Their main product candidates include M-VAX for melanoma, O-VAX for ovarian cancer, and LungVax for non-small cell lung cancer.
What are the main risks for AVXT?
The main risks for AVAX Technologies, Inc. include the potential for clinical trial failures or delays, regulatory hurdles and approval delays, competition from other cancer therapies, and the company's ability to secure additional funding. As an OTC-listed company, AVXT also faces risks related to limited liquidity and transparency. The company's negative profit margin highlights its reliance on future funding or partnerships to sustain operations.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be limited due to the company's OTC status and development stage.